BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261022
DTSTAMP:20260617T114733Z
CREATED:20260617T114733Z
LAST-MODIFIED:20260617T114733Z
UID:43761-1792368000-1792627199@www.pharmajournalist.com
SUMMARY:5th Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:Early Access Programmes have evolved into a critical\, but increasingly complex\, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines\, evidence generation\, and patient access across global markets. \nThe 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning that strategy into execution. As regulatory expectations shift\, reimbursement timelines extend\, and programmes scale globally\, organisations must make more decisions\, earlier\, and with greater consequence. \nThis is the only European forum dedicated to the operational reality of early access – bringing together 140+ leaders across Medical Affairs\, Access\, Regulatory\, Clinical Operations\, and Supply to share how programmes are being designed\, adapted\, and delivered in practice. \nWhether you are building your first programme\, scaling across regions\, or managing a global access portfolio\, this is your opportunity to benchmark your approach\, challenge your assumptions\, and leave with the insight needed to make smarter decisions and deliver earlier\, sustainable access for patients in 2026 and beyond. \nFor more information and to register online\, please click here.
URL:http://www.pharmajournalist.com/event/5th-operationalise-early-access-programmes-summit-europe/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261020
DTEND;VALUE=DATE:20261023
DTSTAMP:20260630T110639Z
CREATED:20260630T110639Z
LAST-MODIFIED:20260630T110639Z
UID:43858-1792454400-1792713599@www.pharmajournalist.com
SUMMARY:4th Covalent Drug Discovery & Development Summit
DESCRIPTION:4th Covalent Drug Discovery & Development Summit (October 20–22\, Boston\, MA) \nCovalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns\, advances in chemistry\, screening technologies\, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology. \nAs the field evolves\, the challenge is no longer proving potential. The priority is successful clinical translation. From predicting off-target toxicity to optimizing PK/PD and dose selection\, teams continue to face uncertainty when moving from discovery into the clinic. Many programs still encounter critical gaps in translating promising preclinical data into patient outcomes. \nThe 4th Covalent Drug Discovery & Development Summit is the only industry-led forum dedicated to bridging discovery through to clinical application. Designed to unite medicinal chemists\, chemical biologists\, translational scientists\, and early clinical leaders\, the meeting delivers a truly end-to-end perspective across covalent drug development\, now with expanded clinical content reflecting the growing pipeline of first-in-human and Phase II programs. \nAcross two conference days and interactive workshops\, attendees will gain practical\, actionable insights to: \n\nDesign safer\, more selective covalent compounds using novel warheads and structure-guided approaches\nDe-risk development through advanced toxicity\, reactivity\, and safety assessment strategies\nIntegrate translational data to improve in vitro to in vivo correlation and support confident clinical decisions\nExpand the druggable space by targeting new residues and previously undruggable biology\n\nWith case studies spanning AI-driven discovery\, chemoproteomics\, kinetic assays\, and translational workflows\, the summit showcases how the field is moving beyond traditional targets and into next-generation covalent therapies. \nBringing together 80+ senior leaders from pharma\, biotech\, and academia\, this is a highly curated environment for deep technical exchange\, collaboration\, and real-world problem solving. \nWhether you are optimizing discovery\, scaling translational strategy\, or preparing for the clinic\, this is the critical forum to understand what it truly takes to move covalent therapies from concept to clinic and to help shape the next wave of precision medicines.
URL:http://www.pharmajournalist.com/event/4th-covalent-drug-discovery-development-summit/
LOCATION:Hampton Inn Boston Seaport District\, 670 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261030
DTSTAMP:20260609T083754Z
CREATED:20260609T083754Z
LAST-MODIFIED:20260609T083754Z
UID:43704-1792972800-1793318399@www.pharmajournalist.com
SUMMARY:9th TPD & Induced Proximity Summit
DESCRIPTION:After a decade of innovation\, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026\, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already\, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone. \nHowever\, following the risk-averse funding environment of 2025\, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development\, it is designed to help you discover the best novel targets\, optimize your degrader profile\, and accelerate your pipelines to the clinic and beyond. \nView the full event guide.
URL:http://www.pharmajournalist.com/event/9th-tpd-induced-proximity-summit/
LOCATION:The Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260703T090227Z
CREATED:20260703T090227Z
LAST-MODIFIED:20260703T090227Z
UID:43883-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:9th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston\, MA\, on November 10–12\, 2026\, as the industry’s only dedicated meeting focused exclusively on RNA-targeted small molecules\, bringing together leading minds from biotech\, pharma and academia to advance the next generation of RNA-focused therapeutics. \nAs momentum continues to build across the field\, driven by recent clinical progress and increasing investment in RNA-targeted approaches\, the summit will explore the latest advances in direct RNA binding\, splice modulation\, RNA degradation\, covalent translation inhibition\, epitranscriptomic regulation and condensate biology. Attendees will gain valuable insights into how researchers are overcoming historic challenges in RNA druggability to develop new treatments for oncology\, rare genetic diseases and neurodegenerative disorders. \nA refreshed 2026 agenda will feature expert-led presentations\, case studies\, panel discussions and interactive workshops covering functional RNA target selection\, structure-guided design\, productive chemical space and emerging RNA-targeting technologies. Delegates will also discover practical strategies for improving screening approaches\, measuring selectivity\, validating targets and accelerating translation from discovery into clinical development. \nThe summit is expected to welcome 80+ RNA-targeted drug discovery experts and 22+ world-class speakers\, including representatives from PTC Therapeutics\, AstraZeneca\, Sanofi\, ReviR Therapeutics\, Remix Therapeutics\, Arrakis Therapeutics\, Dewpoint Therapeutics and Syrna Therapeutics. Through dedicated networking opportunities and collaborative discussions\, attendees will connect with the scientists\, innovators and decision-makers shaping the future of RNA-targeted medicines. \nWhether you are focused on RNA biology\, medicinal chemistry\, drug discovery\, translational research or therapeutic development\, this summit offers an unparalleled opportunity to access cutting-edge data\, exchange ideas with pioneers in the field and help drive the next wave of innovation in RNA-targeted small molecule therapeutics. As the field continues to mature\, the 9th RNA-Targeted Drug Discovery & Development Summit remains the must-attend forum for staying at the forefront of RNA drug discovery.
URL:http://www.pharmajournalist.com/event/9th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR